Eli Lilly continues to do what it does best, which is to capture the obesity and type 2 diabetes treatment markets at an extremely rapid pace. So, sales of its flagship franchise called tirzepatide ...
Researchers at USF Health are making dramatic strides in understanding how new opioid compounds work inside the body to ...
The company delivered 45% revenue growth in Q1 2025, driven by ZEPBOUND and MOUNJARO's strong performance in the obesity and diabetes markets. ZEPBOUND outperformed Novo Nordisk's WEGOVY in terms of ...
Patients are often stabilised for years on somatostatin analogues; however, progression eventually necessitates ...
A study from St. Jude Children's Research Hospital uncovered an alternative binding pocket within nuclear receptors, revealing a much-needed new therapy route for this important class of drug targets.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback